14 min
IgAN: Predicting risk and treatment response | With Dr Andrew Bomback Nephrology Knowledge into Practice Podcast
-
- Medicine
IgA nephropathy presents with a clinically diverse set of symptoms of wide-ranging severity and a varied disease course. As our understanding of IgA nephropathy has improved, various tools have been developed to help assess risk of progression to kidney failure.
This episode offers insight into the use of freely available tools that can assist with the management of IgA nephropathy. We are joined by Dr Andrew Bomback to discuss how these tools are applied in the clinic.
By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.
References:
1. Penfold RS, et al. Primary IgA nephropathy: current challenges and future prospects. Int J Nephrol Renovasc Dis. 2018;11:137-148.
2. Rodrigues JC, et al. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4): 677-686.
3. Trimarchi H et al. Oxford classification of IgA nephropathy 2016: An update from IgA nephropathy classification working groups. Kidney Int 2017;91(5):1014–1021.
4. Barbour S et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med 2019;179(7):942-952.
5. International IgAN Prediction Tool at Biopsy. Available at: https://qxmd.com/calculate/calculator_499/international-igan-prediction-tool. Accessed May 2022.
6. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–S276.
7. Thompson A et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 2019;14:469–481.
Disclosures:
Dr Andrew Bomback declares the following:
Consultant: Travere Therapeutics, Calliditas Therapeutics
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
Funding:
This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.
IgA nephropathy presents with a clinically diverse set of symptoms of wide-ranging severity and a varied disease course. As our understanding of IgA nephropathy has improved, various tools have been developed to help assess risk of progression to kidney failure.
This episode offers insight into the use of freely available tools that can assist with the management of IgA nephropathy. We are joined by Dr Andrew Bomback to discuss how these tools are applied in the clinic.
By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.
References:
1. Penfold RS, et al. Primary IgA nephropathy: current challenges and future prospects. Int J Nephrol Renovasc Dis. 2018;11:137-148.
2. Rodrigues JC, et al. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4): 677-686.
3. Trimarchi H et al. Oxford classification of IgA nephropathy 2016: An update from IgA nephropathy classification working groups. Kidney Int 2017;91(5):1014–1021.
4. Barbour S et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med 2019;179(7):942-952.
5. International IgAN Prediction Tool at Biopsy. Available at: https://qxmd.com/calculate/calculator_499/international-igan-prediction-tool. Accessed May 2022.
6. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–S276.
7. Thompson A et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 2019;14:469–481.
Disclosures:
Dr Andrew Bomback declares the following:
Consultant: Travere Therapeutics, Calliditas Therapeutics
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
Funding:
This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.
14 min